Showing 2779 results
-
Press release /Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was well-…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als…
-
Event /Novartis announces the company’s financial results for the first quarter of 2026.
-
Event /Novartis will announce the company’s financial results for the third quarter of 2026.
-
Event /Novartis will announce the company’s financial results for the second quarter and first half of 2026.